3 Dividend Stocks Worth Buying Now?
Thanks to surging stock prices over the past two years, dividend yields on major stock indices have fallen to fairly low levels. The S&P 500, for instance, currently carries an average yield of just 1.3%.
The mature companies in the Dow Jones Industrial Average fare a bit better, and some of them offer yields that exceed the S&P 500 several times over. » Read more about: 3 Dividend Stocks Worth Buying Now? »
Read More
1 Cloud SaaS Healthcare Stock to Buy on the Dip?
It might surprise many that Veeva Systems Inc. (NYSE:VEEV), best known for its cloud-based software solutions tailored to the life sciences industry, has maintained a core principle of putting customer success and product excellence ahead of short-term gains.
In a market crowded with SaaS companies seeking to serve a wide variety of enterprises,
» Read more about: 1 Cloud SaaS Healthcare Stock to Buy on the Dip? »
Read More
NVIDIA Investing In Tiny Robotics Firm, Should You Follow?
NVIDIA gets a lot of attention for designing some of the world’s most powerful GPUs. It’s difficult to imagine that the recent advancements in artificial intelligence would have happened without NVIDIA. After all, OpenAI trained ChatGPT with 10,000 NVIDIA GPUs connected to a Microsoft supercomputer.
But NVIDIA actually does much more than build efficient processing units.
» Read more about: NVIDIA Investing In Tiny Robotics Firm, Should You Follow? »
Read More
Is Michael Saylor’s Bet Crazy: Bull vs Bear
Microstrategy (NASDAQ:MSTR) and its CEO Michael Saylor are in large part confounding valuation experts worldwide.
The traditional method of valuing a company goes something like this. Analyze the cash flows a company will produce over its lifetime, discount them back to present day, sum them up and arrive at a fair market valuation for the company.
» Read more about: Is Michael Saylor’s Bet Crazy: Bull vs Bear »
Read More
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Is 2025 The Year Uber Bounces Back?
Shares of Uber Technologies (NYSE:UBER) have had a rough few months, dropping 15.7% over the last 90 days even as the overall market finished 2024 on a high note. With shares still sold off, investors may find themselves wondering where Uber goes from here. Let’s take a look at what’s driving UBER down,
» Read more about: Is 2025 The Year Uber Bounces Back? »
Read MoreThe Spotlight
Will Costco Finally Split Its Sky High Stock?
Costco’s stock price has experienced enormous growth over the last few years. At the beginning of 2020, you could purchase a share for a little less than $300. Today, shares trade for closer to $1,000.
Not surprisingly, this growth has encouraged a lot of analysts to speculate about when Costco will split its shares.
» Read more about: Will Costco Finally Split Its Sky High Stock? »
Read MoreThe Daily
6 mutual funds down by over 20% from 52-week high NAVs. Time for a comeback?
Out of 659 equity mutual funds available currently, six equity mutual funds are down by over 20% from their 52-week high NAVs, an analysis by ETMutualFunds showed. Quant PSU Fund was down by 23% at Rs 9.93 from its 52-week high NAV of Rs 12.86.
» Read more about: 6 mutual funds down by over 20% from 52-week high NAVs. Time for a comeback? »